||Naringin is a flavanone glycoside, which exerts a variety of pharmacological effects such as antioxidant activity, blood lipid lowering, anticancer ac
||Calcifediol is an active metabolite of vitamin D. It can inhibit the secretion of parathyroid hormone with 2 nM and commonly used as an indicator of b
||Ketoconazole is an imidazole anti-fungal agent which inhibits cyclosporine oxidase and testosterone 6 beta-hydroxylase with IC50 of 0.19 mM and 0.22 m
||GSK1324726A is an inhibitor of BET proteins BRD2, BRD3, BRD4 with IC50 of 41 nM, 31 nM, and 22 nM respectively.
||Cilengitide is a cyclic RGD pentapeptide antagonist of integrins αvβ3, αvβ5 and α5β1.
||CPI-0610 is an inhibitor of BET bromodomains BRD2, BRD3, BRD4, and BRDT via binding to the acetylated lysine recognition motifs.
||UNC0642 is a selective inhibitor of G9a/GLP with IC50 of < 15 nM.
||ETC-159 is a potent, orally available PORCN inhibitor. It inhibits β-catenin reporter activity with an IC50 of 2.9 nM.
||Vipadenant is an adenosine antagonist with Ki of 1.3 nM and 68 nM for A2A and A1, respectively. Vipadenant is a selective A2A receptor antagonist wit
||CFI-402257 is a novel and selective Mps1 inhibitor with Ki value of 0.1 nM.
||GSK2982772 is an inhibitor of receptor interacting protein 1 (RIP1) with IC50 of 16 nM and it is used for the treatment of inflammatory diseases.
||IVA-337 is a agonist of peroxisome proliferator-activated receptors (PPAR) which is widely used in the study of lung fibrosis and pulmonary hypertensi
||Lifitegrast is a novel small molecule integrin antagonist which can inhibit an integrin, lymphocyte function-associated antigen 1 (LFA-1), from bindin
||Fevipiprant is a selective, potent, reversible competitive CRTh2 antagonist with an in vitro dissociation constant KD value of 1.1nM at the CRTh2 rece
||GSK2193874 is a selective transient receptor potential vanilloid 4 (TRPV4) blocker with IC50 value of 0.04 μM.
||GNE-9605 is a selective and potent LRRK2 with IC50 value of 18.7 nM.
||RBC8 is an inhibitor of GTPases RalA and RalB with IC50 of 3.5 μM in cell assay.
||AZD9496 is a selective antagonist of estrogen receptor Erα (IC50 = 0.28 nM).
||GLPG1690, a first-in-class autotaxin (ATX) inhibitor with IC50 of 131 nM and Ki of 15 nMl, is able to cause a sustained reduction of LPA levels in pla
||GLPG-1837 is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator1, shows enhanced efficacy on CFTR mutants harboring Class III mu
||AZD0364 is an ERK1 and/or ERK2 kinase for the treatment of cancer.
||AMG-3969 is a glucokinase-GKRP disruptor with IC50 value of 343nM and potently reverses the inhibitory effect of GKRP on GK activity.
||WT161 selectively inhibits HDAC6 that exhibits effective anti-tumor activities in multiple myeloma.
||PF-4136309 is a potent, Selective, and orally bioavailable CCR2 antagonist.
||AZD0156 is a potent and selective inhibitors of ATM kinase, with potential chemo-/radio-sensitizing and antineoplastic activities.
||UNBS5162 is a naphthalimide and a hydrolysis product of UNBS3157 that decreases CXCL chemokine expression in experimental prostate cancers and the mea
||GNE-3511 is a potent and selective zipper kinase (DLK, MAP3K12) inhibitors.
||MGL-3196 is a selective thyroid hormone receptor β agonist with EC50s of 0.21 and 3.74 µM for TRβ and TRα respectively.
||PT2385 is an inhibitor of hypoxia inducible factor (HIF)-2 alpha with antineoplastic effect.
||PRQ620 is a highly potent and selective mTORC1/2 inhibitor, shows anti-tumor effects in vitro and in vivo.
||Leniolisib is a potent and selective PI3Kδ inhibitor currently in used for the treatment of immunodeficiency disorders.
||Velpatasvir is an inhibitor of hepatitis C virus nonstructural protein 5A (NS5A) (genotype 1 (GT1) to GT6 replicons).
||PFI-1 is a highly selective BET (bromodomain-containing protein) inhibitor for BRD4 with IC50 of 0.22 μM and for BRD2 with IC50 of 98 nM in a cell-fre
||Elagolix sodium is an antagonist of human GnRH receptor (GnRHR) with IC50 and Ki of 0.25 nM and 3.7 nM, respectively.
||AZD1981 is a potent and selective CRTh2 antagonist and displaces radio-labelled PGD2 from human recombinant DP2 with high potency (pIC50 = 8.4).
||BMS-309403 is an inhibitor of fatty acid binding protein 4 (FABP4) with Ki of less than 2 nM that decreases fatty acid uptake in adipocytes in vitro.
||Potent and selective TRPA1 antagonist (IC50 = 0.02 μM for human TRPA1). Exhibits no siginificant activity against human TRPV1 or TRPV4, and rat TRPV1,
||LXH254 is an ATP-competitive inhibitor of Raf with anti-proliferative activity. Phase I.
||Risdiplam is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN)
||Tropifexor is a potent agonist of FXR with EC50 of 0.26 nM.
||VTX-27 is an inhibitor of protein kinase C θ (PKC θ) and PKC δ with Kis of 0.08 nM and 16 nM, respectively.
||Acrizanib is a selective VEGFR2 inhibitor with IC50 value of 17.4nM.
||TUG-1375 is a free fatty acid receptor 2 (FFA2/GPR43) inhibitor with pKi of 6.69.
||JNJ-61432059 is an oral active and selective negative modulator of AMPAR associated with trans-membrane AMPAR regulatory protein (TARP) γ-8, with a pI
||GSK-2894631A is a highly potent and selective HPGDS inhibitor with IC50 value of 9.9nM.
||AMG 333 is a potent and selective TRPM8 antagonist with IC50 value of 13nM.
||JAK/HDAC-IN-1 is a potent JAK2/HDAC dual inhibitor with improved antiproliferative and proapoptotic activities over SAHA and ruxolitinib in several he
||A-420983 is a potent lck inhibitor, exhibiting oral efficacy in animal models of delayed-type hypersensitivity and organ transplant rejection.
||DDD107498 is a multiple-stage antimalarial agent targeting on eEF2.
||MK-7246 is a potent and selective CRTH2 antagonist with Ki value of 2.5nM.